

Date 20 Oct 2017

Wynford House
Lufton Way
Lufton
Yeovil
Somerset
BA22 8HR

Tel: 01935 384000
Fax: 01935 384079

somccg.enquiries@nhs.net

Somerset CCG Prescribing and Medicines Management Committee Formulary decision – Freestyle Libre sensors.

Dear Colleagues

Following the announcement that freestyle libre sensors would be entering the drug tariff in November 2017 the Somerset CCG PAMM reviewed the evidence base and a number of potential formulary options raised by local and national groups.

The recommendation from PAMM is;

Freestyle Libre – RESTRICTED USE ONLY

Freestyle Libre should ONLY be an option for patients with type 1 diabetes (>4yrs old), who have demonstrated that they are well motivated to manage all of the clinical risks associated with their condition (not just HbA1c) and are also educated to respond to the information provided by freestyle libre.

The patient's GP believes that a clinical need will be fulfilled by the provision of freestyle libre in motivating the patient to achieve and maintain better clinical outcomes.

The patient's GP believes that the patient's current use of blood glucose testing strips will be reduced by the use of Freestyle Libre.

The recommendation from PAMM is the above and following criteria should be applied to all existing patients who are currently self-funding freestyle libre and all new patient requests.

The CCG will monitor uptake of freestyle libre and reserves the right to revisit its formulary recommendation should use exceed expectation and/or be seen to be used in patients outside of the agreed criteria below.

CRITERIA – All applicable for initial prescribing and ongoing prescribing – (certain clinical exceptions to the criteria will apply for children with Type1 diabetes)

The patient's GP should have a record that;

- The patient has type 1 diabetes and has expressed an interest in having NHS access to freestyle libre
- the patient has completed a structured diabetes education programme (all new patients and those diagnosed within the last 3 years)
- the patient had an influenza immunisation in the preceding 1st August – 31st March period
- the patient has had a foot examination and risk classification in the preceding 12 months
- the patient has had a digital retinal screening check in the preceding 12 months
- the patient has had a blood pressure check in the preceding 12 months and achieved a BP of <140/80
- the patient has had a serum cholesterol check in the preceding 12 months and achieved a cholesterol of <5mmol/l
- the patient has had their smoking status checked and updated in the preceding 12 months and they are a non smoker
- the patient has had their HbA1c checked in the preceding 9 months and achieved a value which is <58mmol/l
- the patient had had a check of their serum creatinine (or egfr) in the preceding 12 months
- the patient has had a check of their urine albumin/creatinine ratio in the preceding 12 months
- the patient has had a check of their BMI in the preceding 12 months and achieved a value <30

AND

- The patient has been switched to a formulary blood glucose meter and test strips (<£10 per 50, unless they are in an agreed exempt category eg patient with associated insulin pump)

Freestyle Libra is NOT recommended for prescribing for Type 2 Diabetic patients

Shaun Green – Head of Medicines Management and Clinical Effectiveness